Press Releases

Press Releases

    Date Title View
    09/29/23
    Summary ToggleNew Analysis Highlights Importance of Adhering to Uninterrupted Full Course of Treatment with TEPEZZA® (teprotumumab-trbw) to Support Thyroid Eye Disease (TED) Patient Outcomes
    PDF Version
    09/26/23
    Summary ToggleHorizon Therapeutics plc Named to U.S. News & World Report’s 2024 List of Best Companies to Work For in the Health Care Industry
    PDF Version
    09/25/23
    Summary ToggleRule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
    PDF Version
    09/19/23
    Summary ToggleHorizon Therapeutics plc Ranks Number One on the Fortune Best Workplaces in Biopharma 2023 List
    PDF Version
    09/13/23
    Summary ToggleQ32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of Bempikibart (formerly ADX-914) for Severe Alopecia Areata
    PDF Version
    09/06/23
    Summary ToggleHorizon Therapeutics plc (“Horizon”) Rule 2.12 Announcement
    PDF Version
    09/05/23
    Summary ToggleHorizon Therapeutics Announces Date of Irish Court Hearing to Sanction Scheme of Arrangement
    PDF Version
    09/01/23
    Summary ToggleAMGEN AND HORIZON THERAPEUTICS PLC RESOLVE FTC LAWSUIT, CLEARING PATH TO CLOSE ACQUISITION
    PDF Version
    08/23/23
    Summary ToggleHorizon Therapeutics plc Ranks First in Overall Corporate Reputation by Rare Disease Patient Advocacy Groups
    PDF Version
    08/09/23
    Summary ToggleHorizon Therapeutics plc - Rule 2.12 Announcement
    PDF Version
    Displaying 1 - 10 of 789 results